Neurology Practice Data for Neuromodulation Device Sales

Neurology Is a Sub-Specialty-Driven Market

There are approximately 20,000 practicing neurologists in the United States, according to the American Academy of Neurology (AAN). That sounds like a manageable market to cover. But neurology isn't one market. It's at least 8 distinct sub-specialty markets, each with different clinical workflows, different purchasing patterns, and different decision-making structures.

A movement disorder specialist implanting deep brain stimulation (DBS) devices has almost nothing in common with a general neurologist managing headache patients in a community practice. They treat different conditions, use different equipment, prescribe different drugs, and operate in different clinical settings. The only thing they share is an NPI taxonomy code.

If you're selling neuromodulation devices (DBS, VNS, TMS, spinal cord stimulators), neurological pharmaceuticals (migraine, epilepsy, MS, Parkinson's drugs), or diagnostic equipment (EEG, EMG, neuroimaging), your data needs to resolve neurology into its component sub-specialties. Otherwise you're burning rep time on providers who will never buy your product.

The Neurology Sub-Specialty Map

Here's how the neurology market segments by sub-specialty, and why each one matters for different product categories.

Epileptology (Epilepsy Specialists)

Epileptologists are the primary targets for VNS (vagus nerve stimulation) devices, responsive neurostimulation (RNS) devices, and anti-seizure medications. There are roughly 1,500-2,000 epileptologists in the U.S., most of them concentrated at comprehensive epilepsy centers. These centers are typically academic or large multi-specialty groups with dedicated epilepsy monitoring units (EMUs).

Data needs for epileptology targeting:

• Confirmation of epilepsy sub-specialization (not just general neurology with some epilepsy patients)
• Epilepsy center affiliation and whether the center has an EMU
• Surgical epilepsy program (indicates higher device purchasing for implantable neuromodulation)
• Academic vs. Community setting (academic centers tend to be earlier adopters of new devices)
• Clinical trial participation (indicates willingness to try new technologies)

Movement Disorders

Movement disorder specialists are the primary implanters and referral sources for DBS devices. The DBS market is dominated by Medtronic, Abbott (St. Jude), and Boston Scientific. There are approximately 1,000-1,500 movement disorder neurologists in the U.S., with the majority at academic medical centers.

This is one of the most concentrated sub-specialty markets in all of healthcare. A handful of high-volume DBS centers implant a disproportionate share of all devices. The top 50 centers probably account for 60-70% of DBS volume nationally. Your data strategy here isn't about breadth. It's about depth at key accounts.

Key data fields: DBS implant privileges and volume estimates, academic appointment details, Parkinson's disease center affiliation, relationship to functional neurosurgery programs (DBS is implanted by neurosurgeons, but neurologists select patients and manage programming), and referral network mapping.

Headache Medicine

Headache specialists represent the fastest-growing neurology sub-specialty market for both pharma and devices. The CGRP inhibitor drug class (Aimovig, Ajovy, Emgality, Vyepti, Nurtec, Qulipta) has created a multibillion-dollar pharma market. Neuromodulation devices for headache (Cefaly, SpringTMS, gammaCore) are a smaller but growing segment.

There are approximately 1,500-2,000 neurologists who identify as headache specialists. But here's the data challenge: headache medicine is practiced by a much broader group. General neurologists, primary care physicians, pain management specialists, and even some psychiatrists treat chronic headache patients. The prescribing base for CGRP inhibitors extends well beyond certified headache specialists.

For pharma reps selling migraine drugs, the target list needs to be stratified:

1. Tier 1: UCNS-certified headache medicine specialists (roughly 700-800 providers). These are high-volume prescribers and KOLs.
2. Tier 2: General neurologists with significant headache patient volume (identifiable from practice website analysis and claims patterns). This adds 3,000-5,000 providers.
3. Tier 3: Primary care and other providers who prescribe CGRP inhibitors at meaningful volume. Much larger group, but lower per-provider value.

Neuromuscular Medicine

Neuromuscular specialists treat conditions like ALS, myasthenia gravis, muscular dystrophies, and peripheral neuropathies. This sub-specialty is relevant for: gene therapy products (Zolgensma for SMA, emerging ALS therapies), immunotherapy drugs, EMG/NCS diagnostic equipment, and assistive technology.

There are roughly 800-1,200 neuromuscular specialists, heavily concentrated at academic MDA (Muscular Dystrophy Association) care centers and ALS Association certified treatment centers. The certified center list is publicly available and provides an excellent starting point for data building.

Multiple Sclerosis (MS)

MS specialists represent a high-value pharma target. The MS drug market exceeds $25 billion annually, with 20+ approved disease-modifying therapies. MS specialists are the primary prescribers of these high-cost ($50K-$100K per year) medications.

There are approximately 1,000-1,500 neurologists who focus primarily on MS. Key data for this segment: MS center affiliation, participation in MS clinical trials, infusion center capability (many MS drugs are administered via infusion), and specialty pharmacy relationships.

The National MS Society maintains a partner provider list that's a useful starting point, but it's far from complete. Cross-referencing with NPI data, practice website analysis, and publication records provides a more complete picture.

Neuro-Oncology

Neuro-oncologists treat brain tumors and nervous system cancers. A smaller sub-specialty (500-700 providers), almost exclusively at academic cancer centers and NCI-designated comprehensive cancer centers. Relevant for: chemotherapy agents, tumor treating fields devices (Optune by Novocure), clinical trial recruitment, and diagnostic imaging equipment.

Sleep Neurology

Neurologists with sleep medicine certification treat narcolepsy, sleep-related epilepsy, and other neurological sleep disorders. This overlaps with pulmonology sleep medicine. Relevant for: wake-promoting agents (Wakix, Xywav), CPAP and adaptive servo-ventilation devices, and sleep diagnostic equipment. Data needs to distinguish neurology-trained sleep specialists from pulmonology-trained ones because their prescribing patterns differ.

Behavioral/Cognitive Neurology

This emerging sub-specialty focuses on dementia, Alzheimer's disease, and cognitive disorders. With the approval of anti-amyloid therapies (Leqembi, Kisunla), this segment has become a high-value pharma target. Infusion centers capable of administering these drugs and monitoring for ARIA (brain swelling/bleeding side effects) are the key data targets.

Academic vs. Community Neurology: Different Sales Motions

The academic-community split matters more in neurology than in almost any other specialty. Here's why.

Academic Neurology

Academic neurologists work at university medical centers and teaching hospitals. They tend to be sub-specialized, involved in research, and early adopters of new therapies. They also have less individual purchasing authority because hospital purchasing committees control most buying decisions.

For neuromodulation device companies, academic centers are where you build clinical evidence and KOL relationships. Device adoption starts here and filters out to community practice. Your data for academic targets needs:

• Department chair and division chief identification
• Clinical trial principal investigator (PI) status
• Publication record (indicates KOL status and therapeutic focus)
• Hospital purchasing committee contacts (materials management, OR directors)
• Fellowship training program status (indicates higher procedure volume)

Community Neurology

Community neurologists are generalists by necessity. A community neurologist in a mid-sized city might see headache patients in the morning, an MS patient after lunch, and an epilepsy follow-up in the afternoon. They're less likely to implant devices themselves but are critical referral sources for device-implanting centers.

For pharma, community neurologists often represent the highest prescription volume per provider because they manage more patients independently without academic colleagues to share the panel. Your data for community targets needs:

• Practice ownership (solo vs. Group vs. Hospital-employed)
• Sub-specialty interest areas (even generalists tend to lean toward certain conditions)
• Referral relationships to academic centers (for device companies building referral networks)
• Formulary decision involvement (community neurologists may have more influence over their practice's formulary than academic neurologists who follow institutional formularies)

Neuromodulation Device Sales: The Data You Need

Neuromodulation is a $7+ billion global market growing at 10-12% annually, according to BLS healthcare workforce projections and industry analyst reports. The main device categories relevant to neurology are:

Deep Brain Stimulation (DBS)

DBS systems are implanted surgically to treat Parkinson's disease, essential tremor, dystonia, and (investigationally) OCD, depression, and epilepsy. The implanting surgeon is a functional neurosurgeon, but the referring neurologist (usually a movement disorder specialist) selects patients and manages device programming post-implant.

Your data pipeline needs both sides: the neurosurgeon who implants and the neurologist who refers. These two providers may be at the same institution or at different ones. Mapping this referral relationship is where most neurology databases fall short.

Key data points for DBS targeting:

• Movement disorder specialists with DBS programming privileges
• Functional neurosurgeons with DBS implant volume
• Centers with dedicated DBS/movement disorders programs
• Current device brand in use (Medtronic, Abbott, or Boston Scientific installed base)
• Patient volume indicators for Parkinson's, essential tremor, and dystonia

Vagus Nerve Stimulation (VNS)

VNS (primarily LivaNova's VNS Therapy) is used for drug-resistant epilepsy and treatment-resistant depression. The surgical implant is typically performed by a neurosurgeon, with the epileptologist managing patient selection and device parameters.

Target data: epileptologists at comprehensive epilepsy centers, pediatric epileptologists (VNS is common in pediatric populations), neurosurgeons who perform VNS implants, and centers with surgical epilepsy programs.

Transcranial Magnetic Stimulation (TMS)

TMS is non-invasive and primarily used for treatment-resistant depression, though indications are expanding to include migraine, OCD, and smoking cessation. Unlike DBS and VNS, TMS doesn't require surgery. It's administered in outpatient settings, often at dedicated TMS clinics.

TMS has a unique data profile because the operators span neurology, psychiatry, and dedicated TMS clinics. Our TMS therapy CRM and marketing guide covers this segment in detail. For neurology-specific TMS targeting, focus on headache neurologists (for migraine TMS) and academic epileptologists exploring investigational TMS protocols.

Spinal Cord Stimulation (SCS)

SCS devices are primarily in the pain management domain (interventional pain physicians and neurosurgeons), not general neurology. However, neurologists who specialize in chronic pain, particularly neuropathic pain, are referral sources. Include them in your referral network mapping but don't target them as implanters.

Pharma Sales Into Neurology: Data Segmentation by Drug Category

Neurology pharma is a $50+ billion market with distinct segments that require different data approaches.

Migraine (CGRP Inhibitors and Acute Treatments)

The CGRP class alone exceeds $8 billion in annual sales. Prescribers include headache specialists, general neurologists, and increasingly primary care physicians. Data stratification by prescribing tier (as outlined in the headache section above) is essential. Also track: infusion vs. Self-injectable vs. Oral preference (affects which CGRP products are relevant), prior authorization experience by payer, and patient volume estimates.

Epilepsy (Anti-Seizure Medications)

25+ anti-seizure medications on the market. New entrants (cenobamate/Xcopri is a recent example) need to reach epileptologists first, then filter to general neurologists. Data needs: epilepsy patient volume, current prescribing patterns for competing drugs, formulary status at the provider's affiliated institutions, and willingness to try newer agents (indicated by clinical trial participation or early adoption history).

Multiple Sclerosis (Disease-Modifying Therapies)

20+ DMTs ranging from injectables to oral agents to infusions. The market is highly competitive. Data segmentation for MS pharma: MS patient panel size, current DMT prescribing mix, infusion center capability and capacity, specialty pharmacy affiliations, and involvement in MS registries or clinical trials.

Parkinson's Disease

Levodopa/carbidopa formulations (including Duopa for advanced PD), dopamine agonists, MAO-B inhibitors, and COMT inhibitors. Movement disorder specialists are Tier 1 targets. General neurologists with PD patient volume are Tier 2. Data fields: movement disorders fellowship training, DBS referral patterns (indicating advanced PD patient management), and involvement in PD clinical trials.

Alzheimer's Disease and Dementia

The approval of anti-amyloid antibodies (lecanemab, donanemab) created a new high-value pharma segment in neurology. These drugs cost $26,000+ annually per patient and require infusion administration and ARIA monitoring via MRI. Your data needs to identify: behavioral/cognitive neurologists, geriatric neurologists, memory clinics with infusion capability, and practices with amyloid PET imaging or CSF biomarker testing capacity.

Diagnostic Equipment Sales: EEG, EMG, and Neuroimaging

Neurology diagnostic equipment is a capital expenditure market similar to device sales but with different decision-makers.

EEG Equipment

Electroencephalography is a core neurology diagnostic tool. Targets: epilepsy centers (for long-term monitoring equipment), community neurology practices (for routine EEG), sleep labs (for polysomnography), and ICU programs (for continuous EEG monitoring). The ambulatory EEG segment is growing as home-based monitoring becomes more feasible.

EMG/NCS Equipment

Electromyography and nerve conduction studies are performed by neuromuscular specialists, general neurologists, and physical medicine/rehab physicians. Practice ownership is key here. Hospital-employed neurologists use hospital equipment. Practice-owning neurologists buy their own. Your data needs to distinguish between the two.

Neuroimaging

MRI, PET, and CT are typically hospital purchases, not individual neurologist purchases. However, some large neurology groups are investing in in-office MRI (low-field MRI devices like Hyperfine's Swoop). Target data: practice size, ownership structure, and clinical focus areas that drive imaging volume (MS, stroke, dementia).

Building a Neurology Target List: Practical Steps

Here's the workflow for creating an actionable neurology database.

Step 1: Start With NPI and Layer Sub-Specialty Classification

Pull all providers with neurology taxonomy codes (2084N0400X for Neurology, plus sub-taxonomy codes). Then classify by sub-specialty using: UCNS certification records (headache, neuromuscular, neuro-oncology, behavioral neurology), fellowship training data, practice website analysis, and publication/research focus areas.

Step 2: Map Academic vs. Community

Cross-reference with academic medical center databases and teaching hospital affiliations. Identify department chairs, division chiefs, and fellowship directors. These are your KOLs and early adopters. For community neurologists, identify practice ownership and group size. Visit our neurology provider data page for more on how we build these segments.

Step 3: Add Device and Procedure-Specific Indicators

For neuromodulation companies: identify providers with implant privileges, DBS programming certification, VNS experience, and TMS administration capability. For pharma: identify prescribing patterns by drug category using claims-derived indicators or practice focus analysis.

Step 4: Build the Decision-Maker Map

Neurology purchasing decisions involve multiple stakeholders. For devices at academic centers: the neurologist who champions the product, the neurosurgeon who implants it, the department chair who approves the relationship, and the hospital purchasing/value analysis committee. Your data should capture all four roles for each target institution.

Step 5: Enrich with Contact Data

Direct email addresses, phone numbers, and LinkedIn profiles for each decision-maker. Academic neurologists are often reachable through their institutional email. Community neurologists through practice direct lines. For a deep dive on reaching medical device company targets in specialty practices, see our industry guide.

Common Mistakes in Neurology Data

Mistake 1: Treating Neurology as One Market

The biggest mistake device and pharma companies make is targeting "neurologists" as if they're interchangeable. A DBS pitch to a headache neurologist wastes everyone's time. A CGRP inhibitor pitch to a movement disorder specialist does the same. Sub-specialty classification isn't optional. It's the foundation of effective neurology targeting.

Mistake 2: Ignoring the Neurosurgeon Relationship

Neuromodulation devices are implanted by neurosurgeons but prescribed/referred by neurologists. If your data only includes one side of this equation, your field team is working with half the picture. Map the referral relationships between neurologists and neurosurgeons at each target institution.

Mistake 3: Overlooking Pediatric Neurology

Pediatric neurologists (child neurology) are a separate sub-specialty with approximately 2,000 practitioners. They're the primary targets for pediatric epilepsy devices (VNS), certain anti-seizure medications, and rare disease therapies (SMA, Dravet syndrome, Lennox-Gastaut). Pediatric neurology taxonomy codes are different from adult neurology codes. If your data pull uses only adult taxonomy codes, you're missing this entire segment.

Mistake 4: Stale Academic Appointment Data

Academic neurologists change institutions more frequently than community providers. A department chair who moved from Johns Hopkins to UCSF 6 months ago is a completely different sales opportunity in a different territory. Your data needs to reflect current affiliations, not last year's faculty directory.

What Good Neurology Data Looks Like

For each neurology provider, your database should include at minimum:

• NPI and demographics: name, credentials, NPI number, practice address(es)
• Sub-specialty classification: epileptology, movement disorders, headache, neuromuscular, MS, neuro-oncology, behavioral/cognitive, or general neurology
• Practice setting: academic, community group, solo, hospital-employed
• Clinical focus indicators: procedures performed, conditions treated, device programming capabilities
• Decision-maker role: department chair, division chief, fellowship director, practice owner, employed physician
• Contact data: direct email, phone, LinkedIn profile
• Institutional affiliations: hospital, health system, academic department, certified center memberships

If your current neurology data only has NPI, address, and a generic "neurology" specialty tag, you're operating at about 20% of what's possible. The sub-specialty layer, practice setting classification, and decision-maker identification are what turn a list into an actionable sales tool.

Want to see the difference? Request a sample of Provyx neurology data with full sub-specialty classification and compare it to what you're working with today.